Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …

Patients with schizophrenia have increased mortality and morbidity compared with the
general population. These patients have a 20-year shorter lifespan than peers without …

Second generation antipsychotics (SGAs), such as clozapine, olanzapine, risperidone and
quetiapine, are among the most effective therapies to stabilize symptoms schizophrenia (SZ) …

AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis
and a central player in glucose and lipid metabolism, is potentially implicated in the …

Alzheimer's disease (AD) is the general consequence of dementia and is diagnostic
neuropathology by the cumulation of amyloid-beta (Aβ) protein aggregates, which are …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in the world and one of the leading indications for liver transplantation. It is one of the many …

The action of protein kinases and protein phosphatases is essential for multiple
physiological responses. Each protein kinase displays its own unique substrate specificity …

Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even
greater in patients who are taking second-generation antipsychotics (SGAs). SGAs …

Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease
in patients with schizophrenia. However, the clinical features of olanzapine-induced …